Study Design: Longitudinal evaluation of disease progression, from diagnosis to treatment, among commercially insured enrollees with chronic HCV.
Methods: We validated and used algorithms derived from standardized procedure and diagnosis codes to identify enrollees with chronic HCV in large insurance claims databases to describe the HCV care cascade, including the proportion engaged in HCV-specific care (13 possible definitions), the proportion prescribed HCV treatment, and the proportion who received an HCV RNA test 30 or more days after initiating treatment.
Results: Approximately 90% of individuals with an HCV RNA test procedure code followed by either 3 or more chronic HCV diagnosis codes on different service dates or 2 or more chronic HCV diagnosis codes separated by more than 60 days truly had chronic HCV. Using these algorithms, we identified 5791 HCV cases from January 1, 2013, to June 30, 2014. Among enrollees with HCV, 95% were engaged in HCV care, but only 49% initiated treatment and 43% received a follow-up HCV RNA test 30 or more days after initiating treatment.
Conclusions: With validated case-finding algorithms, insurance claims data can be used to describe and monitor portions of the HCV care cascade. Although nearly all enrollees with HCV were engaged in HCV care, only half received treatment, indicating that even commercially insured enrollees may find it challenging to access treatment.
Am J Manag Care. 2018;24(5):232-238Takeaway Points
Just half of commercially insured enrollees identified by our validated hepatitis C virus (HCV) case-finding algorithms were prescribed HCV treatment, highlighting the need for improved treatment access.
- With the use of validated case-finding algorithms, researchers can describe and monitor the HCV care cascade using administrative healthcare data and identify potential targets for public health intervention.
- This is the first study to describe the cascade among commercially insured enrollees from a large nationally representative claims database.
- Analyses are underway to identify factors impacting progression along the HCV care cascade, from diagnosis to treatment, among infected enrollees in this commercially insured population.
An estimated 3.5 million individuals are currently living with hepatitis C virus (HCV) infection in the United States,1 more than half of whom are unaware of their status.2,3 Although 81% of infected individuals were born between 1945 and 1965 (defined as the birth cohort),4 new HCV infections among younger individuals have increased in recent years.5 Approximately 75% to 85% of acutely infected individuals develop chronic HCV,6 which is associated with increased risk of chronic liver disease, hepatocellular carcinoma, and death.7-9 With the availability of highly effective direct-acting antiviral (DAA) medications, virologic cure can be achieved for more than 90% of treated patients with 8 to 12 weeks of therapy.10,11 It is critical to monitor how well patients proceed along the HCV care cascade, including appropriate testing, engagement in HCV-specific care (eg, liver disease staging), treatment, and confirmation of virologic cure. Such measures across the cascade could provide important baselines for comparison and highlight factors impacting progression along the cascade, thereby informing targets for improved clinical care and public health intervention.
Although a growing body of research describes the care cascade in a variety of populations and settings across the United States, the data are based on small studies and theoretical models.12-27 The various methods, settings, and populations under study make it challenging to directly compare findings. Additionally, investigators are limited by the information captured within each data source when determining which steps can be assessed and what metrics are appropriate. Therefore, it is necessary to utilize a variety of data sources to generate an accurate depiction of the HCV care cascade on a national scale to include different types of health insurance coverage (such as commercial, public, and uninsured) and those populations at high risk for HCV infection (such as individuals with a history of injection drug use).
Although not representative of all individuals infected with HCV in the United States, commercial insurance claims databases contain clinical and pharmacy data on millions of individuals. In particular, claims data can be used to monitor national trends in HCV testing.28 However, because laboratory test results are not included in claims data, they cannot be used to determine serostatus among those who had an HCV antibody test or identify individuals confirmed to be positive for HCV by HCV RNA detection. Claims data are limited to standard procedure and diagnosis codes for identifying enrollees with a particular disease condition, which may result in misclassification.29
Although algorithms for identifying chronic HCV infection among enrollees with diagnosed liver cirrhosis have been published,30,31 no algorithm is available to accurately identify enrollees with chronic HCV infection, irrespective of liver disease stage, using standard procedure and diagnosis codes derived from insurance claims data. Using a large commercial insurance claims database, we sought to both validate algorithms to identify enrollees living with chronic HCV and to describe the care cascade among the identified cases.
We obtained enrollment information and insurance claims from Truven Health Analytics MarketScan commercial and Medicare Supplemental Insurance claims databases from 2010 through 2014. These nationally representative data include more than 100 million covered lives, including both commercially insured enrollees younger than 65 years and Medicare-eligible enrollees 65 years or older with employer-sponsored supplemental insurance coverage.32 Laboratory test results were available in a separate data set for a subset of approximately 3 million enrollees included in the claims database, with linkage using unique identification numbers.
This secondary analysis of deidentified insurance claims data did not require institutional review board approval. All analyses were conducted using SAS software, version 9.3 (SAS; Cary, North Carolina).
Study population. Using Logical Observation Identifiers Names and Codes,33 we identified all enrollees with at least 1 quantitative or qualitative HCV RNA result in the laboratory test results database from January 1, 2011, to December 31, 2014. Quantitative HCV RNA tests were considered positive if the viral load was 36.2 IU/mL or higher.34 As some enrollees had several HCV RNA test results available during the study period, the HCV RNA index date was defined by the first positive result among enrollees who were ever positive and the first negative result among enrollees who were always negative. We included enrollees 18 years or older who had prescription drug coverage and no claim for HCV treatment in the 6 months prior to the HCV RNA index date. We also required at least 6 months of continuous enrollment both before and after the HCV RNA index date, limiting the analysis to enrollees with an index date between January 1, 2011, and June 30, 2014 (Figure 1A).
Developing and testing algorithms. Using Current Procedural Terminology (CPT) codes for an HCV RNA test (87520, 87521, or 87522) and various combinations of International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) codes for HCV infection (070.41, 070.44, 070.51, 070.54, 070.70, 070.71, and V02.62), we developed and tested the accuracy of 9 algorithms to identify chronic HCV cases using inpatient and outpatient claims data (Table 1). Using the HCV RNA index test results as the gold standard, we calculated the sensitivity, specificity, positive predictive value (PPV), and negative predictive value for each algorithm. Our goal was to describe the HCV care cascade among enrollees with chronic HCV; thus, we selected algorithms with the highest PPV for most accurate case identification.
HCV Care Cascade
Study population. To target the era of DAA treatment regimens, we identified claims for RNA testing from inpatient and outpatient files from January 1, 2013, to June 30, 2014. Claims were deduplicated by service date to identify each enrollee’s first test during the study period, defined as the RNA CPT index date. Enrollees 18 years or older with at least 6 months of continuous enrollment both before and after the RNA CPT index date, prescription drug coverage, and no treatment for HCV during the 6-month look-back period were included in the analysis (Figure 1B). We then applied the 2 algorithms with the highest PPV from the validation study and described enrollees living with chronic HCV by age group, birth cohort, sex, US Census division, and insurance plan type.
Defining and describing the cascade. To describe the care cascade, we examined inpatient, outpatient, and pharmacy claims between the RNA CPT index date and December 31, 2014, for each enrollee. Enrollees had between 6 and 24 months of claims data available for review, depending on when their RNA CPT index date and dates of continuous enrollment occurred.
Among enrollees with chronic HCV, we calculated the proportions who were engaged in HCV-specific care, were actually treated for HCV, and received an HCV RNA test 30 or more days after initiating treatment. Enrollees were considered to be engaged in HCV-specific care if they met at least 1 of 13 definitions of engagement (Table 2) or if they were prescribed HCV treatment but did not meet any of our 13 definitions of engagement. These definitions included different diagnostic tests or procedures used to stage or monitor the progression of liver disease. Enrollees were identified as having initiated treatment if at least 1 outpatient pharmacy claim included a National Drug Code for an FDA-approved drug to treat HCV.35 We also calculated the proportion of those treated who ever received a DAA as part of their treatment regimen and described the DAA types dispensed. Finally, we calculated the proportion of enrollees who received a follow-up HCV RNA test by CPT code 30 or more days after initiating HCV treatment, because an RNA test is currently recommended for monitoring individuals during antiviral therapy36 and serves as an indicator for continued engagement in care.
We identified 6983 eligible enrollees in the laboratory test results dataset with at least 1 HCV RNA test result between January 1, 2011, and June 30, 2014; 3037 (43%) were HCV RNA—positive. Algorithm 9, an HCV RNA test followed by 3 or more chronic HCV ICD-9-CM diagnosis codes on different service dates, yielded a PPV of 90%. Algorithms 7 and 8, an HCV RNA CPT code followed by 2 or more chronic HCV ICD-9-CM codes separated by more than 60 days, and an HCV RNA CPT code followed by 2 or more chronic HCV ICD-9-CM codes separated by more than 90 days, respectively, each yielded a PPV of 89% (Table 1). We elected to apply algorithms 7 and 9 to the full claims database to maximize the number of cases identified.
HCV Care Cascade
From January 1, 2013, through June 30, 2014, we identified 88,509 unique enrollees with an HCV RNA test who met our study criteria. Of these, 5791 enrollees with chronic HCV were identified by 1 or both of the algorithms (Table 3). Half (51%; n = 2981) of this population was aged 50 to 59 years, with 4816 (83%) included in the birth cohort and 55% enrolled in preferred provider organization plans. Males made up 64% of the population, which was also geographically diverse.
Engagement in HCV-specific care. Among the 5791 enrollees with HCV, 5360 met at least 1 definition of engagement in HCV-specific care (Figure 2). We also included 145 enrollees who were prescribed HCV treatment but did not meet any of our 13 definitions of engagement as engaged in HCV-specific care. These individuals were likely to have been evaluated prior to receiving HCV treatment, but their evaluation events were not captured in these claims data. Therefore, 5505 enrollees within our cohort of chronic HCV cases (95%) were engaged in HCV-specific care following HCV RNA testing. The most common definitions for engagement in care were through the identification of a gastrointestinal or infectious disease specialist provider type (77%), abdominal ultrasound (44%), hepatic function panel (36%), and genotyping (30%) (Table 2).
Initiation of HCV treatment and follow-up RNA testing. Of those enrollees identified as having chronic HCV, 2843 (49%) had a claim for HCV treatment, with 2633 of those patients (93%) receiving a DAA medication as part of their treatment regimen. Among those prescribed DAAs, 75% received sofosbuvir, 10% received sofosbuvir and ledipasvir, 11% received telaprevir, 4% received boceprevir, and 1 enrollee received ombitasvir, paritaprevir, and ritonavir (data not shown). Among those who initiated HCV treatment, 2475 (87%) had at least 1 follow-up HCV RNA test 30 or more days after their first HCV treatment claim. Among those prescribed DAAs, 1489 (57%) had at least 1 HCV RNA test 20 or more weeks after initiating treatment (data not shown).
This is the first study to validate algorithms for identifying individuals living with HCV that utilized a large insurance claims database and HCV RNA laboratory test results linked to claims. Two of the 9 algorithms we tested had high PPVs, 90% and 89%, respectively, for detecting cases of HCV. The ability to correctly identify individuals with current HCV infection in administrative data is an important first step toward understanding the quality of clinical management and treatment and supporting strategic changes for quality improvement. Among those identified by the algorithms, we found that 95% of enrollees with chronic HCV were engaged in HCV-specific care and 49% initiated HCV treatment. Although the relatively high proportion engaged in HCV-specific care is encouraging, our findings highlight that even individuals with commercial insurance coverage may find it challenging to access HCV treatment.37-39 Increased access can be demonstrated over time through monitoring the cascade at a national level using large administrative databases, including Medicare and Medicaid.
Administrative healthcare data have been used to develop algorithms for identifying persons diagnosed with HCV among patients with cirrhosis.30,31 Kramer et al and Niu et al found that identifying 1 to 3 HCV ICD-9-CM codes of any type resulted in PPVs as high as 93% and 97%, respectively, among HCV-infected enrollees with cirrhosis compared with electronic health record data. We did not limit our analysis to enrollees diagnosed with cirrhosis, and we observed an improvement in PPV when we tested algorithms including only codes for chronic HCV (070.44 or 070.54). Although the sole use of these 2 codes resulted in reduced sensitivity, our aim was to identify the algorithms with the highest PPVs so that we could increase the probability of identifying true cases for describing the chronic HCV care cascade.
HCV Care Cascade
Engagement in HCV-specific care. Insurance claims data provide an opportunity to identify several laboratory tests, diagnostic procedures, or specialty provider visits that can be used to demonstrate that enrollees are engaged in HCV-specific care. We elected to use 13 definitions in an attempt to identify as many engaged enrollees as possible. Other investigators have defined engagement in different ways, such as referral for HCV care,18,20,22 1 or more visits with a healthcare provider or specialist,12,13,16,21,23-25,27 and a certain number of HCV tests within a specified time period.23,26
Although 95% of enrollees with chronic HCV were engaged in HCV-specific care in our study, the observed or estimated proportion of engaged study participants varies widely among other published cascades, from as low as 6% up to 89%,21,23 demonstrating potential effects of variation in study setting, population, and methodology on observed estimations of engagement. In addition, we found that 77% of enrollees with chronic HCV were engaged in HCV-specific care through a visit with either a gastrointestinal or infectious disease specialist. Among previously published cascades, the highest reported proportion of enrollees positive for HCV attending a specialty visit for HCV care was 52%.15 The relatively higher proportion we observed may reflect better access to, and retention in, care among a commercially insured population.
HCV genotype testing is recommended for all individuals chronically infected with HCV to guide providers in selecting the most appropriate treatment regimen.40 We found that just 30% of enrollees with HCV received a genotype test after their HCV RNA CPT index date. However, we used this metric to define engagement in care after diagnosis of HCV infection, and genotype tests are often done on the same date as the HCV RNA test; therefore, 30% is a minimum estimate of the true proportion that were ever genotype-tested. That proportion has been reported to be as low as 6.1% and as high as 75.4% in previously published cascades.14,16
Initiation of HCV treatment and follow-up RNA testing. Just less than half of the enrollees in the cascade study group initiated HCV treatment by the end of the study period. As we only required a minimum of 6 months of continuous enrollment following the HCV RNA CPT index date, we may not have captured all treatment events for enrollees in this population who had less observation time. However, our minimum estimate is higher than values reported in other published cascades, which range from 3% to 46%.12,13,15,16,18-27 This may reflect the advantage of studying a commercially insured population in care in the era of DAA treatment regimens.
Our finding that 75% of those who initiated HCV treatment were prescribed sofosbuvir is not unexpected considering the timing of our study period and the FDA approval of sofosbuvir in December 2013. Additionally, although we do not have laboratory results to determine who among our care cascade study group ultimately achieved virologic cure, we did determine that 87% of treated enrollees continued to be engaged in care through follow-up RNA testing 30 or more days after initiating treatment.
Our study is subject to certain limitations. First, these analyses were conducted among a subset of commercially insured enrollees and are not generalizable to all HCV-infected individuals in the United States. Second, it is possible that enrollees included in the validation study were misclassified by HCV RNA test result if enrollees we classified as always negative had a positive test result prior to January 1, 2011. Third, because we selected algorithms based on PPV to maximize accuracy, our algorithms may not be suitable for other evaluations, such as estimating HCV prevalence.
Finally, we were not able to describe the care cascade for HCV-infected enrollees in MarketScan who were not identified by the algorithms. However, among 1098 enrollees testing positive for HCV RNA identified in the MarketScan laboratory test results subset, during the same time period, we found that 79% were engaged in HCV-specific care and just 30% initiated treatment (data not shown). It is not surprising that fewer enrollees in the RNA-positive subset were engaged and subsequently treated, as our algorithms selected individuals based on chronic HCV diagnosis codes documented at healthcare encounters; individuals not having chronic HCV-related encounters will not be selected. It is possible that we have selected enrollees who were already exhibiting signs of advanced liver disease and prioritized for treatment. Additional analyses are under way to further examine the differences between the cascades developed using the validated algorithms and the subset of enrollees with laboratory test results.
We have successfully validated 2 algorithms to identify cases of chronic HCV in claims data and described the HCV care cascade among those identified by the algorithms. In addition to utilizing these algorithms to identify cases of HCV in other sources of claims data, analyses are under way to identify predictors of progression along the cascade. Although 95% of enrollees chronically infected with HCV were engaged in HCV care and 49% initiated HCV treatment, our findings indicate that commercially insured enrollees in care may still find it challenging to access HCV treatment. Additionally, a previous analysis of trends in HCV antibody testing among MarketScan enrollees demonstrated that just 3% of individuals born from 1945 to 1965 and 2% of persons born in other years received an antibody test in 2014,28 highlighting a clear need for improved uptake of national testing recommendations.6 It will be important to continue to monitor the HCV care cascade over time to ensure that all individuals living with HCV receive recommended care and treatment.
The authors would like to acknowledge the contributions of Lauren Canary, Liesl Hagan, Dr Aaron Harris, and Dr Alexander Millman, who assisted with the creation of an inclusive list of ways insured enrollees could be engaged in HCV-specific care.
The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the CDC.Author Affiliations: Partnerships and Evaluation Branch, Division of Health Informatics and Surveillance (CI), and Meningitis and Vaccine Preventable Diseases Branch, Division of Bacterial Diseases (SH), and Prevention Branch, Division of Viral Hepatitis (CV), CDC, Atlanta, GA.
Source of Funding: None.
Author Disclosures: The authors report no relationship or financial interest with any entity that would pose a conflict of interest with the subject matter of this article.
Authorship Information: Concept and design (CI, SH, CV); analysis and interpretation of data (CI, SH, CV); drafting of the manuscript (CI, CV); critical revision of the manuscript for important intellectual content (CI, SH, CV); statistical analysis (CI); and supervision (SH, CV).
Address Correspondence to: Cheryl Isenhour, DVM, MPH, Mailstop E-91, Division of Health Informatics and Surveillance, CDC, 1600 Clifton Rd, Atlanta, GA 30329. Email: firstname.lastname@example.org.REFERENCES
1. Edlin BR, Eckhardt BJ, Shu MA, Holmberg SD, Swan T. Toward a more accurate estimate of the prevalence of hepatitis C in the United States. Hepatology. 2015;62(5):1353-1363. doi: 10.1002/hep.27978.
2. Denniston MM, Klevens RM, McQuillan GM, Jiles RB. Awareness of infection, knowledge of hepatitis C, and medical follow-up among individuals testing positive for hepatitis C: National Health and Nutrition Examination Survey 2001-2008. Hepatology. 2012;55(6):1652-1661. doi: 10.1002/hep.25556.
3. Kuniholm MH, Jung M, Del Amo J, et al. Awareness of hepatitis C virus seropositivity and chronic infection in the Hispanic Community Health Study/Study of Latinos (HCHS/SOL). J Immigr Minor Health. 2016;18(6):1257-1265. doi: 10.1007/s10903-016-0350-1.
4. Denniston MM, Jiles RB, Drobeniuc J, et al. Chronic hepatitis C virus infection in the United States, National Health and Nutrition Examination Survey 2003 to 2010. Ann Intern Med. 2014;160(5):293-300. doi: 10.7326/M13-1133.
5. Surveillance for viral hepatitis — United States, 2014: hepatitis C. CDC website. cdc.gov/hepatitis/statistics/2014surveillance/commentary.htm#hepatitisC. Updated June 22, 2016. Accessed November 9, 2016.
6. Smith BD, Morgan RL, Beckett GA, et al; CDC. Recommendations for the identification of chronic hepatitis C virus infection among persons born during 1945-1965. MMWR Recomm Rep. 2012;61(RR-4):1-32.
7. Kanwal F, Hoang T, Kramer JR, et al. Increasing prevalence of HCC and cirrhosis in patients with chronic hepatitis C virus infection. Gastroenterology. 2011;140(4):1182-1188.e1. doi: 10.1053/j.gastro.2010.12.032.
8. El-Serag HB, Kanwal F. Epidemiology of hepatocellular carcinoma in the United States: where are we? where do we go? Hepatology. 2014;60(5):1767-1775. doi: 10.1002/hep.27222.
9. Ly KN, Hughes EM, Jiles RB, Holmberg SD. Rising mortality associated with hepatitis C virus in the United States, 2003-2013. Clin Infect Dis. 2016;62(10):1287-1288. doi: 10.1093/cid/ciw111.
10. Smith-Palmer J, Cerri K, Valentine W. Achieving sustained virologic response in hepatitis C: a systematic review of the clinical, economic and quality of life benefits. BMC Infect Dis. 2015;15:19. doi: 10.1186/s12879-015-0748-8.
11. Walker DR, Pedrosa MC, Manthena SR, Patel N, Marx SE. Early view of the effectiveness of new direct-acting antiviral (DAA) regimens in patients with hepatitis C virus (HCV). Adv Ther. 2015;32(11):1117-1127. doi: 10.1007/s12325-015-0258-5.
12. Cachay ER, Hill L, Wyles D, et al. The hepatitis C cascade of care among HIV infected patients: a call to address ongoing barriers to care. PLoS One. 2014;9(7):e102883. doi: 10.1371/journal.pone.0102883.
13. Hawks L, Norton BL, Cunningham CO, Fox AD. The hepatitis C virus treatment cascade at an urban postincarceration transitions clinic. J Viral Hepat. 2016;23(6):473-478. doi: 10.1111/jvh.12512.
14. Jonas MC, Rodriguez CV, Redd J, Sloane DA, Winston BJ, Loftus BC. Streamlining screening to treatment: the hepatitis C cascade of care at Kaiser Permanente Mid-Atlantic States. Clin Infect Dis. 2016;62(10):1290-1296. doi: 10.1093/cid/ciw086.
15. Linas BP, Barter DM, Leff JA, et al. The hepatitis C cascade of care: identifying priorities to improve clinical outcomes. PLoS One. 2014;9(5):e97317. doi: 10.1371/journal.pone.0097317.
16. Maier MM, Ross DB, Chartier M, Belperio PS, Backus LI. Cascade of care for hepatitis C virus infection within the US Veterans Health Administration. Am J Public Health. 2016;106(2):353-358. doi: 10.2105/AJPH.2015.302927.
17. Meyer JP, Moghimi Y, Marcus R, Lim JK, Litwin AH, Altice FL. Evidence-based interventions to enhance assessment, treatment, and adherence in the chronic hepatitis C care continuum. Int J Drug Policy. 2015;26(10):922-935. doi: 10.1016/j.drugpo.2015.05.002.
18. Norton BL, Southern WN, Steinman M, et al. No differences in achieving hepatitis C virus care milestones between patients identified by birth cohort or risk-based screening. Clin Gastroenterol Hepatol. 2016;14(9):1356-1360. doi: 10.1016/j.cgh.2016.04.017.
19. Yehia BR, Schranz AJ, Umscheid CA, Lo Re V 3rd. The treatment cascade for chronic hepatitis C virus infection in the United States: a systematic review and meta-analysis. PLoS One. 2014;9(7):e101554. doi: 10.1371/journal.pone.0101554.
20. Holmberg SD, Spradling PR, Moorman AC, Denniston MM. Hepatitis C in the United States. N Engl J Med. 2013;368(20):1859-1861. doi: 10.1056/NEJMp1302973.
21. Falade-Nwulia O, Mehta SH, Lasola J, et al. Public health clinic-based hepatitis C testing and linkage to care in Baltimore. J Viral Hepat. 2016;23(5):366-374. doi: 10.1111/jvh.12507.
22. Trooskin SB, Poceta J, Towey CM, et al. Results from a geographically focused, community-based HCV screening, linkage-to-care and patient navigation program. J Gen Intern Med. 2015;30(7):950-957. doi: 10.1007/s11606-015-3209-6.
23. Viner K, Kuncio D, Newbern EC, Johnson CC. The continuum of hepatitis C testing and care. Hepatology. 2015;61(3):783-789. doi: 10.1002/hep.27584.
24. Anderson ES, Galbraith JW, Deering LJ, et al. Continuum of care for HCV among patients diagnosed in the emergency department setting. Clin Infect Dis. 2017;64(11):1540-1546. doi: 10.1093/cid/cix163.
25. Ford MM, Jordan AE, Johnson N, et al. Check Hep C: a community-based approach to hepatitis C diagnosis and linkage to care in high-risk populations. J Public Health Manag Pract. 2018;24(1):41-48. doi: 10.1097/PHH.0000000000000519.
26. Noska AJ, Belperio PS, Loomis TP, O’Toole TP, Backus LI. Engagement in the hepatitis C care cascade among homeless veterans, 2015. Public Health Rep. 2017;132(2):136-139. doi: 10.1177/0033354916689610.
27. Norton BL, Beitin A, Glenn M, DeLuca J, Litwin AH, Cunningham CO. Retention in buprenorphine treatment is associated with improved HCV care outcomes. J Subst Abuse Treat. 2017;75:38-42. doi: 10.1016/j.jsat.2017.01.015.
28. Isenhour CJ, Hariri SH, Hales CM, Vellozzi CJ. Hepatitis C antibody testing in a commercially insured population, 2005-2014. Am J Prev Med. 2017;52(5):625-631. doi: 10.1016/j.amepre.2016.12.016.
29. O’Malley KJ, Cook KF, Price MD, Wildes KR, Hurdle JF, Ashton CM. Measuring diagnoses: ICD code accuracy. Health Serv Res. 2005;40(5 pt 2):1620-1639. doi: 10.1111/j.1475-6773.2005.00444.x.
30. Kramer JR, Davila JA, Miller ED, Richardson P, Giordano TP, El-Serag HB. The validity of viral hepatitis and chronic liver disease diagnoses in Veterans Affairs administrative databases. Aliment Pharmacol Ther. 2008;27(3):274-282. doi: 10.1111/j.1365-2036.2007.03572.x.
31. Niu B, Forde KA, Goldberg DS. Coding algorithms for identifying patients with cirrhosis and hepatitis B or C virus using administrative data. Pharmacoepidemiol Drug Saf. 2015;24(1):107-111. doi: 10.1002/pds.3721.
32. MarketScan. Truven Health website. truvenhealth.com/your-healthcare-focus/government/analytic-research/marketscan. Accessed October 11, 2016.
33. LOINC website. loinc.org. Accessed February 1, 2016.
34. Wiesmann F, Naeth G, Sarrazin C, et al. Variation analysis of six HCV viral load assays using low viremic HCV samples in the range of the clinical decision points for HCV protease inhibitors. Med Microbiol Immunol. 2015;204(4):515-525. doi: 10.1007/s00430-014-0364-z.
35. National drug code directory. FDA website. www.accessdata.fda.gov/scripts/cder/ndc/index.cfm. Accessed April 26, 2016.
36. Monitoring patients who are starting HCV treatment, are on treatment, or have completed therapy. HCVGuidelines.org website. hcvguidelines.org/evaluate/monitoring. Updated September 21, 2017. Accessed August 1, 2016.
37. King A, Bornschlegel K, Johnson N, Rude E, Laraque F. Barriers to treatment among New York City residents with chronic hepatitis C virus infection, 2014. Public Health Rep. 2016;131(3):430-437. doi: 10.1177/003335491613100309.
38. Edlin BR. Access to treatment for hepatitis C virus infection: time to put patients first. Lancet Infect Dis. 2016;16(9):e196-e201. doi: 10.1016/S1473-3099(16)30005-6.
39. Saab S, Jimenez M, Fong T, et al. Accessibility to oral antiviral therapy for patients with chronic hepatitis C in the United States. J Clin Transl Hepatol. 2016;4(2):76-82. doi: 10.14218/JCTH.2016.00011.
40. Initial treatment of HCV infection. HCVGuidelines.org website. hcvguidelines.org/treatment-naive. Updated September 21, 2017. Accessed November 10, 2016.